Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 1.7% while the Hang Seng is down 1.8%. The Nikkei 225 is trading down by 1.6%. US stocks slid on Friday as a deepening economic crisis in Turkey dragged on bank shares and triggered a move out of riskier assets.
Back home, India share markets have opened the day on a lower note. The BSE Sensex is trading down by 239 points while the NSE Nifty is trading down by 80 points. The BSE Mid Cap index opened and BSE Small Cap index opened the day down by 0.9% & 0.7% respectively.
The rupee is currently trading at 68.95 to the US$.
Sectoral indices have opened the in on a mixed note with information technology stocks and healthcare stocks witnessing maximum buying interest. While, metal stocks and PSU stocks have opened the day in red.
In the news from the pharma sector. As per an article in a leading financial daily, Cipla has received final approval for its abbreviated new drug application (ANDA) for Atazanavir Caps 100mg, 150mg, 200mg, and 300mg from the United States Food and Drug Administration (USFDA).
According to IQVIA (IMS Health), Reyataz and its generic equivalents had US sales of approximately US$324mn for the 12-month period ending April 2018.
Cipla’s Atazanavir Caps 100mg, 150mg, 200mg, and 300mg are an AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Reyataz.
It is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients aged 6 years and older and weighing at least 15 kg.
Cipla share price opened the day up by 0.6%.
Speaking of the pharma sector, the BSE Healthcare Index has been on a roller coaster ride in the past few years. The period from 2012 to 2015 saw the index go up more than three times.
